Carregant...
Tumor mutational burden as a predictive biomarker for checkpoint inhibitor immunotherapy
Immune checkpoint inhibitor (ICI) therapies can achieve meaningful tumor responses in a subset of patients with most types of cancer that have been investigated. However, the majority of patients treated with these drugs do not experience any clinical benefit. Because not all patients benefit from I...
Guardat en:
| Publicat a: | Hum Vaccin Immunother |
|---|---|
| Autors principals: | , , , , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
Taylor & Francis
2019
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7012182/ https://ncbi.nlm.nih.gov/pubmed/31361563 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/21645515.2019.1631136 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|